Finance

Lists
Why is AVTX up 18.85%?
Dive Deeper
AVTX:NASDAQ
Avalo Therapeutics Inc
$8.51
+18.85%
(+1.35) 1D
$8.51
0.00% (0.00)
After hours
Closed: Nov 11, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVTX...
Open
$7.24
High
$8.55
Low
$7.17
Mkt. cap
492.07M
Avg. vol.
2.46M
Volume
1.84M
52-wk high
$24.27
52-wk low
$6.53
EPS
-$2.91
Beta
0.75
Shares outstanding
57.82M
No. of employees
33
Open
$7.24
High
$8.55
Low
$7.17
Mkt. cap
492.07M
Avg. vol.
2.46M
Volume
1.84M
52-wk high
$24.27
52-wk low
$6.53
EPS
-$2.91
Beta
0.75
Shares outstanding
57.82M
No. of employees
33
News stories
From web sources and news partners
About Avalo Therapeutics Inc
CEO-
Employees33
Founded2011
HeadquartersRockville, Pennsylvania, United States
SectorHealth Care
IndustryBiotechnology
Websiteavalotx.com
Analyst ratings
Based on 7 analysts giving stock ratings to AVTX in the past 3 months
Buy
Buy
5
Hold
2
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for AVTX in the last 3 months.
Highest
Current $8.51
$60.00 (+605.05%)
Average
$26.00 (+205.52%)
Lowest
$10.00 (+17.51%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Driscoll
Wedbush
Buy
Reiterated
$20.00
+135%
11/06/2026
Julian Harrison
BTIG
Buy
Maintained
$10.00
+17.5%
11/05/2026
Mitchell Kapoor
H.C. Wainwright
Hold
Reiterated
-
-
11/06/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$24.00
+182%
11/06/2026
Leland Gershell
Oppenheimer
Buy
Maintained
$16.00
+88%
10/26/2026
Yatin Suneja
Guggenheim
Hold
Downgraded
-
-
10/23/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$60.00
+605.1%
10/01/2026
Thomas Smith
Leerink Partners
Buy
Initiated
$38.00
+346.5%
07/06/2026
Stacy Ku
TD Cowen
Buy
Maintained
-
-
06/11/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$39.00
+358.3%
05/15/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$45.00
+428.8%
05/14/2026
Jason Butler
Citizens JMP
Buy
Maintained
$55.00
+546.3%
05/14/2026
Andy Chen
Wolfe Research
Buy
Initiated
$48.00
+464%
04/08/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
59.00K
-
-
-
Cost of goods sold
8.78M
10.15M
19.03M
10.34M
Cost of revenue
8.78M
10.15M
19.03M
10.34M
Research and development expenses
4.48M
3.90M
4.39M
4.70M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.53M
6.85M
8.10M
8.35M
Operating expense
11.02M
10.75M
12.49M
13.06M
Total operating expenses
19.80M
20.90M
31.52M
23.40M
Operating income
-19.74M
-20.90M
-31.52M
-23.40M
Other non operating income
5.17M
480.00K
-7.58M
210.00K
EBT including unusual items
-13.59M
-19.62M
-36.34M
-18.94M
EBT excluding unusual items
-13.59M
-19.62M
-36.34M
-18.94M
Income tax expense
130.00K
12.00K
18.00K
7.00K
Effective tax rate
-0.96%
-0.06%
-0.05%
-0.04%
Other operating expenses
-
-
-
-
Net income
-13.72M
-19.63M
-36.36M
-18.94M
Net profit margin
-23,254.24%
-
-
-
Earnings per share
-0.37
-0.98
-0.83
-0.34
Interest and investment income
984.00K
803.00K
2.76M
4.25M
Interest expense
-
-
-
-
Net interest expenses
984.00K
803.00K
2.76M
4.25M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.73M
-20.88M
-31.50M
-23.38M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps